Leucemia Mieloide Acuta Terapie Innovative. Adriano Venditti Ematologia Universita Tor Vergata, Roma
|
|
- Theresa Lawrence
- 6 years ago
- Views:
Transcription
1 Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma
2 Leucemia Mieloide Acuta Terapie Innovative Adriano Venditti Ematologia Universita Tor Vergata, Roma
3 AML.Current outcome of therapy Age, y CR % DFS % ED% OS % (med) < (24 mo) > (10 mo)
4 Novel cytotoxic drugs Nucleoside analogues Clofarabine Troxacitabine Ester of ARAc Alkylating agents Cloretazine Inhibitors of Ribonucleotide reductase Triapine New strategies in AML Targeted therapy Cell surface antigens Anti-CD33 MoAbs Drug-resistance MDR1 modulators Cellular signaling pathways Kinase inhibition (FLT3, mtor) FT inhibition (RAS) Induction of apoptosis (anti-bcl-2) Proteasome inhibition Angiogenesis Lenalidomide Bevacizumab Epigenetic events Hypomethylating agents, HDACi Others Vaccines (WT1)
5 Clofarabine Resistant to Deamination & Phosphorolysis Fludarabine Cladribine Clofarabine
6 Metabolism and mechanism of action Clofarabine P P P RNR DNA Polymerases dntp pool DNA incorporation Clofarabine P P Clofarabine P dcyd kinase Clofarabine Apoptosome Inhibition of DNA synthesis CELL DEATH
7 Clofarabine in AML Regimen N Population CR+CRi% Clo 31 Rel/Ref 32 1 Clo (Biov-121) 66 Untreated 44 2 Clo + Id-AC 29 Rel/Ref 41 3 Clo + Id-AC 60 Untreated 60 4 Clo + Ld-AC 42 Untreated 63 5 Clo + Hd-AC 23 Rel/Untreated 61 6 Clo + D + GO 37 Untreated Kantarjian et al, Blood 2003; 2 Burnett et al, ASH 2006; 3 Faderl et al, Blood 2005; 4 Faderl et al, Blood 2006; 5 Faderl et al, ASH 2005; 6 Agura et al, ASH 2006; 7 Burnett et al, ASH 2006
8 AML16 intensive: Outline Course 1 Course 2 Demethylation (Azacytidine) D + Ara-C D + Ara-C D + Ara-C + Mylotarg No Treatment vs CR/PR R 2 Demethylation (Azacytidine) D+Clofarabine + Mylotarg D+Clofarabine No Rx No Treatment *Randomise 2 vs 3 courses if at least PR after course 1 Mini-allo after course 2
9 Cloretazine Novel sulfonylhydrazine alkylating agent Phase I dose-finding study in advanced AML (MDACC) 38 pts (28 AML, 5 MDS) 600 mg/m 2 single iv infusion recommended dose for phase II Minimal extramedullary toxicity 1 CR Phase II study in poor risk relapsed AML (MDACC) 53 pts (1st relapse AML; median age 62y) 600 mg/m 2 single iv infusion 2 CR (4%)
10 Cloretazine Phase II multicenter study in elderly untreated poor risk patients with de novo AML or High Risk MDS N= mg/m 2 single iv infusion Risk factors included 60 yrs, ECOG PS, secondary AML, unfavorable cytogenetics, and organ dysfunction Results: Risk Factors Age+0 # of patients 12 CR/CRp (N=33) 7 CR/CRp (%) 58% Age % Age % Age % Currently being evaluated in a multicenter phase III trial in combination with Ara-C in 1st relapse AML Giles et al, JCO 2007
11 MRC AML 15 Schema Course 1 Course 2 Course 3 Course 4 Course 5 ADE ± GO R I S K ADE MACE ± GO MidAc Stop therapy R DA 3+10 ± GO FLAG-Ida ± GO A S S E S S M E N T DA 3+8 FLAG-Ida Ara-C 1.5g/m 2 ± GO AraC 3g/m 2 ± GO Ara-C 1.5g/m 2 Ara-C 3g/m 2 R AraC 1.0g/m 2 Burnett AK et al. ASH Abstract 13
12 MRC AML 15 trial: study design Patients with untreated AML < 60 years of age (N = 1115) Induction: Course 1 ADE ± GO (n = 160) DA ± GO (n = 474) FLAG-Ida ± GO (n = 479) Risk assessment *Consolidation arms included gemtuzumab + chemotherapy. Burnett AK, et al. ASH Abstract 13. To compare three induction schedules (namely ADE, DA and FLAG-Ida) Induction: Course 2 ADE DA CR Second randomization, then To assess the value of GO during FLAG-Ida induction when used in combination with ADE or DA or FLAG-Ida consolidation*
13 MRC AML 15 trial: relapse and DFS No gemtuzumab Gemtuzumab Relapse DFS P =.027 P =.007 Relapse (%) Disease Free (%) Years From CR 0 3 Years From CR Burnett AK, et al. ASH Abstract 13.
14
15
16 MRC AML 15 trial: preliminary results Similar rates of postinduction CR with gemtuzumab + induction vs induction chemotherapy alone 84% vs 86% Similar mortality, resistant disease rate in both groups 8% to 7% Gemtuzumab increased DFS in patients with favorable or intermediate cytogenetics (P <.02) without improvement in overall survival Treatment generally tolerable with similar rates of adverse events in each arm Addition of gemtuzumab to induction chemotherapy may benefit those with favorable/intermediate cytogenetics Burnett AK, et al. ASH Abstract 13.
17 Studies of MDR modulation in AML GROUP MODULATOR REGIMEN OUTCOME SWOG CSP D/HiDAC ± CSP RFS/OS Impr MRC CSP ADE ± CSP No benefit HOVON CSP ME ± CSP No benefit GALGB* PSC-833 ADE ± PSC-833 No benefit ECOG PSC-833 MEC ± PSC-833 No benefit HOVON* PSC-833 DA ± PSC-833 No benefit *De novo > 60 yrs
18 Inhibition of MDR: zosuquidar Selective P-gp inhibitor1 Binds to P-gp with high affinity1 In vitro concentrations of 50100nM circumvent P-gp-mediated resistance 2,3 Does not alter pharmacokinetics of co-administered drugs2 Phase II trial in poor-risk AML CR/CRi 61%4 Can be combined with induction chemo5 1Sato Cancer Res, 1991; 2Dantzig Cancer Res, 1996; 3Green Biochem Pharmacol, 2001; 4Cripe ASH, 2002 (abstr); 5Gerrard Haematologica, 2004
19 ECOG protocol E3999: daunorubicin + cytarabine +/- zosuquidar in older adults Induction Consolidation I Daunorubicin Cytarabine Zosuquidar Daunorubicin Cytarabine Placebo E V A L U A T E CR or MR Cytarabine Consolidation II Daunorubicin Daunorubicin Cytarabine Cytarabine Zosuquidar Placebo Cripe L et al. ASH 2006
20 Median OS (months) MDR status and treatment arm MDR + MDR - P value All Patients 7.8 (n=318) 11.4 (n=63) 0.08 Zosuquidar 7.0 (n=160) 11.7 (n=32) 0.5 P =.523 Placebo 9.2 (n=158) 11.4 (n=31) 0.08 Schedule modified to eliminate neurologic toxicity No difference in OS or CR was seen overall between treatment groups Cripe L et al. ASH 2006
21 FLT3 inhibition in AML FLT3 is expressed at high levels in 70% to 100% of cases of AML FLT3-activating mutations Internal tandem duplication (ITD) and point mutations occur in ~30% of patients with AML Lead to constitutive activation of the tyrosine kinase Stimulate proliferation and inhibit apoptosis of AML cells Important negative prognostic factor Gilliland DG, et al. Blood. 2002;100:1532.
22 FLT3 inhibitors currently in clinical trials in AML MLN-518 (Tandutinib, quinazoline) PKC412 (Staurosporine) SU11248 (Indolinone) CEP701 (Lestaurtinib, indolocarbazole)
23 Studies of FLT3 inhibitors in AML STUDY POPULATION REGIMEN OUTCOME PKC412 can be given SU safely in simultaneous and sequential combination with DHARAc Phase I MLN518 2 Stone et al, ASH 2005 Phase I PKC412 3 Phase II CEP701 4 Phase II Adult refractory Mutated/Wild Adult unfit Mutated/Wild Refractory/Relapsed Mutated Elderly unfit Mutated/Wild mg daily COMBINATION mg twice daily THERAPY CEP701 is synergistic with standard therapy PR in only 4/4 if mut used simultaneously PR in or 2/15 immediately wild following chemo 75 mg 3 times daily 60(80) mg twice daily Antileukemic activity in 5/8 mutated Levis et al, BLOOD 2004 HI in 14/20 HI in 3/5 Mut HI in 5/22 Wild 1 Fiedler et al, BLOOD 2005; 2 De Angelo et al, BLOOD 2006; 3 Stone et al, BLOOD 2005; 4 Knapper et al, BLOOD 2006;
24 Targeting signaling pathways Why Target Ftase? Ftase is an enzyme that modifies proteins for localization to cell membrane Many proteins are farnesylated, some of which are important in cancer development Transforming activity of RAS proteins depends on farnesylation Activating mutations of RAS in 15-30% of AMLs Blocking farnesylation may have therapeutic potential apple Tipifarnib, lonafarnib
25 Phase II study of tipifarnib in AML Poor risk and elderly with untreated AML 158 patients enrolled Age range: years (median: 74) 600 mg twice a day for 21 days CR in 14% ORR = 23% PR or HI 9% 7,3 mos median duration of CR 18 mos median duration of OS in responders Lancet, et al. Blood. 2007
26 Phase II study of tipifarnib in AML Refractory/relapsed AML 252 patients enrolled Age range: years (median: 62) 600 mg twice a day for 21 days CR/CRi in 4% ORR = 11% HI in 7% 12 mos median duration of OS in responders Harousseau, et al. Blood. 2007
27 Epigenetics Targeting epigenetic events Alteration of the heritable state of gene expression causing loss of function (gene silencing) Gene silencing mediated by: DNA methylation (DNA Methyltransferase) Histone de-acetylation (Histone deacetylase) RNA interference (post-transcriptional) MicroRNA Epigenetic events reversible Hypomethylating agents and HDACi in clinical use Azacytidine, Decitabine Valproic acid, SAHA, Depsipeptide
28 Decitabine 5-Azacytidine NH 2 NH 2 N N N HO O N O HO O N O HO OH HO OH Incorporates into DNA Incorporates into RNA Pro-drug for decitabine
29 Azacytidine effective in AML Azacytidine evaluated in patients meeting WHO IWG criteria for AML Phase II/III studies CALGB 8421 (IV administration) CALGB 8921 (S.C. administration) CALGB 9221 (S.C. administration) Dose schedule for all trials: 75 mg/m2/day for 7 days, every 28 days Median response: 279 days % of patients Response Intravenous Azacytidine (n = 25) Subcutaneous Azacytidine (n = 55) Non responders Complete response Partial response Hematologic improvement Silverman LR, et al. ASH Abstract 1848.
30 Phase II decitabine in frontline AML Decitabine 20 mg/m 2 given as IV infusion once daily for 5 days every 4 weeks 42 patients enrolled Median age=73.5 years 28 patients evaluable for response, 25 for safety Overall response: 29%; CR=2, CRc=2, CRi=4 Grade 3/4 Adverse events: febrile neutropenia (32%), dyspnea (20%), hypokalemia (12%), pneumonia (28%), vomiting (8%) Cashen A, et al. ASH 2006
31 Phase I-II study of 5-AZA, VPA and ATRA in AML/HRMDS Untreated/refractory/relapsed AML 53 patients enrolled (4 HRMDS), 19 in the phase I Age range: 5-84 years (median: 69) Schedule: 5-AZA 75 mg/m2 days 1-7, subcutaneously VPA 50, 62.5 and 70 mg/kg days 1-7, orally ATRA 45 mg/m2, days 3-5 CR/CRi in 29% ORR = 42% BM response in 13% 26 weeks median duration of response Soriano, et al. Blood. 2007
32 Phase I study of DAC and VPA in AML To determine the OBD of DAC alone and MTD of VPA + DAC 25 untreated/relapsed AML Age range: years (median: 70) 14 pts treated with DAC alone (d 1-10) 8, 15 mg/m 2 /d 6, 20 mg/m 2 /d OBD 11 pts treated with DAC at OBD + VPA (d 5-21) 3, 15 mg/kg 6, 20 mg/kg encephalopathy 2, 25 mg/kg ORR 52% (11 pts, 4 CR, 4 CRi, 3 PR) Blum et al. JCO. 2007
33 Critical pathways that may be targeted in leukemia stem cells Self-renewal Differentiation PIK3/PTEN JunB/AP-1 pathway Wint/β-Catenin HOX genes Notch BMI-1 Shh LSC Quiescence Apoptosis
34 Upstream activators Rapamycin/Analogs Downstream effectors
35 A Phase I dose escalation study of the mtor inhibitor sirolimus and MEC chemotherapy in AML Sirolimus combinations in AML Salvage: A Dose Finding Phase I Study of Sirolimus + mitoxantrone/etoposide/ara-c sirolimus MTD (12 mg loading dose and then 4 mg daily) MEC (M at 8 mg/m 2 X 5d, E at1 00 mg/m 2 X 5d, ara-c at 1000 mg/m 2 X 5d) N=23 Preliminary Results: CR = 4 (17%) Therapeutic sirolimus levels safely achieved Conclusions: Sirolimus can be combined with chemotherapy Myelosuppression and hepatoxicity (hyperbilirubinemia) is the predominant toxicity Phase II study will be required to test efficacy Luger S, et al Blood 2006
36 Conclusive remarks AML still a challenge, particularly in elderly A wide range of novel agents available for phase III clinical trials ( multitargeted therapy ) New strategies should consider combination therapies LSC targeted therapy
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA
2 Workshop Nazionale SIES Ematologia Traslazionale Nuovi Farmaci e Strategie Terapeutiche nelle LMA Adriano Venditti Ematologia Universita Tor Vergata, Roma Current Treatment Results in AML AGE, y CR%
More informationRisk-adapted therapy of AML in younger adults. Sergio Amadori Tor Vergata University Hospital Rome
Risk-adapted therapy of AML in younger adults Sergio Amadori Tor Vergata University Hospital Rome Pescara 11/2010 AML: treatment outcome Age CR % ED % DFS % OS %
More informationMeet-the-Expert: AML Treating older patients with AML
Meet-the-Expert: AML Treating older patients with AML Sergio Amadori Tor Vergata University Hospital Rome Istanbul 2012 AML in older patients Poor prognosis Minority treated with intensive Cx Treatment
More informationAML in elderly. D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013
AML in elderly D.Selleslag AZ Sint-Jan Brugge, Belgium 14 December 2013 AML is predominantly a disease of the elderly incidence 2 3/100.000 SEER Cancer Statistics, National Cancer Institute, USA 2002 2006
More informationSummary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain
Summary of Key AML Abstracts Presented at the European Hematology Association (EHA) June 22-25, 2017 Madrid, Spain EHA 2017 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://learningcenter.ehaweb.org/eha/#!*listing=3*browseby=2*sortby=1*media=3*ce_id=1181*label=15531
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outline Molecular biology Chemotherapy and Hypomethylating agent Novel Therapy
More informationSafety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naïve Patients Aged 65 Years With Acute Myeloid Leukemia Abstract 102 Wei AH, Strickland SA, Roboz GJ, Hou J-Z, Fiedler W, Lin TL,
More informationOncology Highlights: Leukemia & Myelodysplastic Syndromes
Oncology Highlights: Leukemia & Myelodysplastic Syndromes Jorge Cortes, MD Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Highlights of the Day Leukemia & MDS AML: The field
More informationHow the Treatment of Acute Myeloid Leukemia is Changing in 2019
How the Treatment of Acute Myeloid Leukemia is Changing in 2019 Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Chair, Dept. Hematologic Malignancies Translational Science City
More informationInotuzumab Ozogamicin in ALL. Hagop Kantarjian M.D. May 2016 Bologna, Italy
Inotuzumab Ozogamicin in ALL Hagop Kantarjian M.D. May 2016 Bologna, Italy Immuno Oncology in ALL Monoclonals + cytotoxic agents e.g.inotuzumab Bispecific monoclonals (CD3 + CD19) e.g.blinatumomab Modified
More informationTreatment of Low-Blast Count AML. Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata
Treatment of Low-Blast Count AML Maria Teresa Voso Dipartimento di Biomedicina e Prevenzione Università di Roma Tor Vergata Definition of Low-Blast Count AML Blast counts 20-30%, or > 10%? v Retrospective
More informationASCO 2011: Leukemia. Disclosures
ASCO 2011: Leukemia E.J. Feldman M.D Weill-Cornell Medical College Disclosures Speaker does not report any affiliations 1 V617F JAK2 mutation in MPDs JAK STAT PATHWAY Signal transducers and activators
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationAcute Myeloid Leukemia: State of the Art in 2018
Acute Myeloid Leukemia: State of the Art in 2018 Harry P. Erba, MD, PhD Professor, Department of Medicine Director, Leukemia Program Duke University Durham, NC Treatment Paradigm of Adults with AML Fit
More informationKevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias
Kevin Kelly, MD, Phd Acute Myeloid and Lymphoid Leukemias Relevant financial relationships in the past twelve months by presenter or spouse/partner. Speakers bureau: Novartis, Janssen, Gilead, Bayer The
More informationAML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered
AML IN OLDER PATIENTS Whenever possible, intensive induction therapy should be considered Charles A. Schiffer, M.D. Karmanos Cancer Institute Wayne State University School of Medicine Detroit, MI WHY ARE
More informationESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA. Dr Rob Sellar UCL Cancer Institute, London, UK
ESTABLISHED AND EMERGING THERAPIES FOR ACUTE MYELOID LEUKAEMIA Dr Rob Sellar UCL Cancer Institute, London, UK OVERVIEW Main focus on patients fit for intensive treatment Biological and Clinical Heterogeneity
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More informationWednesday, November 30, 2011 University of Michigan
Wednesday, November 30, 2011 University of Michigan Presenter Gary J. Schiller, MD, FACP Professor, Department of Medicine, Hematology/Oncology Director, Hematological Malignancies/Stem Cell Transplantation
More informationDr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital
Dr Kavita Raj Consultant Haematologist Guys and St Thomas Hospital IPSS scoring system Blood counts Bone marrow blast percentage Cytogenetics Age as a modulator of median survival IPSS Group Median Survival
More informationFrontline Induc.on Therapy in 2017 Alan K Burne+
Frontline Induc.on Therapy in 2017 Alan K Burne+ Ravenna, October 2017 Standard of Care Induc5on: 7+3 Ara-C / Daunorubicin Consolida5on: High Dose Ara-C (3g doses) Total of 4 courses. Myeloabla5ve allogral
More informationInduction therapy for elderly patients with acute myeloid leukemia
Blood Reviews (2008) 22, 311 320 www.elsevier.com/locate/blre REVIEW Induction therapy for elderly patients with acute myeloid leukemia Mike G. Martin*, Camille N. Abboud Section of Bone Marrow Transplantation
More informationAll patients with FLT3 mutant AML should receive midostaurin-based induction therapy. Not so fast!
All patients with FLT3 mutant AML should receive midostaurin-based induction therapy Not so fast! Harry P. Erba, M.D., Ph.D. Professor, Internal Medicine Director, Hematologic Malignancy Program University
More informationSummary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, San Diego CA
Summary of Key AML Abstracts Presented at the American Society of Hematology (ASH) December 2-6, 2016 - San Diego CA ASH 2016 ANNUAL MEETING: ABSTRACT SEARCH PAGE: https://ash.confex.com/ash/2016/webprogram/start.html
More informationDisclosure. Study was sponsored by Karyopharm Therapeutics No financial relationships to disclose Other disclosures:
Combination of Selinexor with High-Dose Cytarabine and Mitoxantrone for Remission Induction in Acute Myeloid Leukemia is Feasible and Tolerable A Phase I Study (NCT02573363) Amy Y. Wang, Howie Weiner,
More informationDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2 Sunesis Pharmaceuticals, Inc, South San Francisco
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) Naval Daver 1, Hagop Kantarjian 1, Guillermo
More information[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014
[ NASDAQ: MEIP ] Analyst & Investor Event December 8, 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may
More informationEvolving Targeted Management of Acute Myeloid Leukemia
Evolving Targeted Management of Acute Myeloid Leukemia Jessica Altman, MD Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives Identify which mutations should be assessed
More informationMolecularly Targeted Therapies - Strategies of the AMLSG
Molecularly Targeted Therapies - Strategies of the AMLSG Richard Schlenk Department of Internal Medicine III Ulm University, Germany Genotype-adapted Leukemia Program NAPOLEON GIMEMA/AMLSG/SAL APL [t(15;17)]
More informationANCO 2015: Treatment advances in acute leukemia
ANCO 2015: Treatment advances in acute leukemia Michaela Liedtke, MD Stanford, CA September 12, 2015!" Disclosures Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Steering Committee
More informationChemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials
d Chemotherapeutic treatment of acute myeloid leukemia: incorporating the results of recent clinical trials Better outcomes for patients with acute myeloid leukemia over the last 30 years have been largely
More informationAcute Myeloid Leukemia Progress at last
Acute Myeloid Leukemia Progress at last Bruno C. Medeiros, MD September 9, 217 Introduction Mechanisms of leukemogenesis Emerging therapies in AML Previously untreated AML Relapsed and refractory patients
More informationThe Evolving Treatment Landscape in AML
The Evolving Treatment Landscape in AML Elias Jabbour, MD Associate Professor Section Chief, Acute Lymphocytic Leukemia Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson
More information39% Treated. 61% Untreated. 33% UnRx. 45% UnRx. 59% UnRx. 80% UnRx
AML in the Elderly สน น ว ส ทธ ศ กด ช ย งานประช มว ชาการกลางป สมาคมโลห ตว ทยาแห งประเทศไทย คร งท 53 25-26 ต ลาคม 2561 ณ โรงแรมเลอ เมอร เด ยน เช ยงใหม จ งหว ดเช ยงใหม 33% UnRx 45% UnRx 59% UnRx 80% UnRx
More informationNew concepts in the management of elderly patients with AML
New concepts in the management of elderly patients with AML Martha L. Arellano, MD Associate Professor of Hematology/Oncology Director, Hematology & Medical Oncology Fellowship Program Winship Cancer Institute
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationEHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication)
EHA 2017 Abstracts: 4 Abstracts ( 1 Oral Presentation, 2 EPosters, 1 Publication) ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS):
More informationLow Risk MDS Scoring System. Prognosis in Low Risk MDS. LR-PSS Validation 9/19/2012
Advances in MDS What s on the Horizon Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Newer Prognostic Systems Hypomethylating agent failures Newer Treatment approaches Role
More informationPersonalized Therapy for Acute Myeloid Leukemia. Patrick Stiff MD Loyola University Medical Center
Personalized Therapy for Acute Myeloid Leukemia Patrick Stiff MD Loyola University Medical Center 708-327-3216 Major groups of Mutations in AML Targets for AML: Is this Achievable? Chronic Myeloid Leukemia:
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationAcute Myeloid Leukemia
Acute Myeloid Leukemia Guido Marcucci, M.D. Director, Gehr Family Center for Leukemia Research Hematologic Malignancies and Stem Cell Transplantation Institute City of Hope Acute Myeloid Leukemia Gene
More informationIPSS Modified 7/27/2011. WHO-Based Prognostic Scoring System (WPSS)
Advances in MDS Treatment: What s on the Horizon? New Prognostic Models and Therapies Jason Gotlib, MD, MS Assistant Professor of Medicine (Hematology) Stanford Cancer Center AA&MDSIF July 3, 011 WHO-Based
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationLAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna
LAM 20-30% Cristina Papayannidis, MD, PhD DIMES, Istituto di Ematologia L. e A. Seràgnoli Università di Bologna FAB CLASSIFICATION OF MYELODYSPLASTIC SYNDROME Subtype % Blood Myeloblasts Bone Marrow Myeloblasts
More informationA paradigm shift in the therapy of low blast count acute myeloid leukemia. Valeria Santini UF Ematologia, Università di Firenze
A paradigm shift in the therapy of low blast count acute myeloid leukemia Valeria Santini UF Ematologia, Università di Firenze Patients (%) AML is predominantly a disease of the elderly 40 69% of patients
More informationNew Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents
New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel Agents Martin S. Tallman The prognosis for younger adults ( 55-60 years) with acute myeloid leukemia (AML)
More informationTargeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD
Targeting CD20 and CD22 in B-cell ALL Daniel J. DeAngelo, MD, PhD Harvard/Dana-Farber Cancer Institute Boston, MA Disclosures for Daniel J. DeAngelo, MD, PhD Royalty Receipt of intellectual property/ Patent
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationUpdates in the Management of Acute Myeloid Leukemia
Updates in the Management of Acute Myeloid Leukemia Lydia Benitez, harmd, BCO 2017 TOA Conference I have no conflicts of interest with relation to the content of this presentation 4 Objectives Describe
More informationDisclosure Slide. Research Support: Onconova Therapeutics, Celgene
Oral Rigosertib Combined with Azacitidine in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS): Effects in Treatment Naïve and Relapsed- Refractory Patients Shyamala C. Navada,
More informationTREATMENT UPDATES IN ACUTE LEUKEMIA. Shannon McCurdy, MD University of Pennsylvania
TREATMENT UPDATES IN ACUTE LEUKEMIA Shannon McCurdy, MD University of Pennsylvania TIMELINE FOR FDA APPROVED AGENTS FOR AML Midostuarin Enasidenib Cytarabine + Daunorubicin (7+3) Gemtuzumab Ozogamicin
More informationASCO 2009 Leukemia MDS -Transplant
ASCO 2009 Leukemia MDS -Transplant Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Scottsdale, AZ, USA mesa.ruben@mayo.edu American Society of Hematology State-of-the-Art Symposium
More informationLA LEUCEMIA SECONDARIA: QUALI OPZIONI TERAPEUTICHE. Livio Pagano Istituto di Ematologia Università Cattolica S. Cuore Roma
LA LEUCEMIA SECONDARIA: QUALI OPZIONI TERAPEUTICHE Livio Pagano Istituto di Ematologia Università Cattolica S. Cuore Roma saml: Incidence In USA, NCI / SEER data - 1998 10,600 new patients with AML / year
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationSpecific Changes: Recommend the addition of sorafenib as an option for salvage therapy for patients with relapsed/refractory FLT3/ITD+ AML.
Mary Ann Watson, Pharm.D. Onyx Pharmaceuticals, Inc 249 E. Grand Ave. South San Francisco, CA 94080 (503) 831-1162 mwatson@onyx.com April 8, 2014 NCCN Acute Myeloid Leukemia Guidelines Panel: On behalf
More informationArecent source data meta-analysis of randomized trials in adults
ARTICLE Acute Myeloid Leukemia EUROPEAN HEMATOLOGY ASSOCIATION Ferrata Storti Foundation Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia:
More informationAcute promyelocytic leukemia
Acute promyelocytic leukemia Laura Cicconi University Tor Vergata Rome, Italy Acute Myeloid Leukemia Meeting Ravenna, Italy (October 2017) APL. From highly fatal to curable disease Fatal outcome if not
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationTreatment of APL. M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r
Treatment of APL M a tth e w M e i, M.D. A s s is ta n t P ro fe s s o r C ity o f H o p e C o m p re h e n s iv e C a n c e r C e n te r Disclosures I have nothing to disclose Objectives 1. Urgency of
More informationMyelodysplastic Syndromes. Post-ASH meeting 2014 Marie-Christiane Vekemans
Myelodysplastic Syndromes Post-ASH meeting 2014 Marie-Christiane Vekemans Agenda New biological developments Risk assessment and prognostic factors New therapeutic options Agenda New biological developments
More informationDisrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference
CYC 682 Disrupting the Cell Cycle to Treat AML and MDS Rodman & Renshaw Conference September 2014 Disclaimer This presentation contains forward-looking statements within the meaning of the safe harbor
More informationIII. AML IN OLDER ADULTS: ARE WE LISTENING?
III. AML IN OLDER ADULTS: ARE WE LISTENING? Mikkael A. Sekeres, MD, MS* AML is a disease of older adults. In the US, the median age is 68 years and the age-adjusted population incidence is 17.6 per 100,000
More information2/10/2017. Updates in Acute Leukemia Therapy Blood Cancer Incidence in the United States, Leukemia Incidence in the Unites States, 2016
Updates in Acute Leukemia Therapy 2017 Aaron Logan, MD, PhD UCSF Division of Malignant Hematology and Blood and Marrow Transplantation aaron.logan@ucsf.edu @hemedoc Blood Cancer Incidence in the United
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Recall the dose-limiting toxicity and preliminary clinical response results with 14- and 21-day extended treatment schedules of daily oral azacitidine. Apply new research
More informationIDH1 AND IDH2 MUTATIONS
Mutant Isocitrate Dehydrogenase (midh) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationLess Intensive Therapy For Older Aml Patients
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2013 Less Intensive Therapy For Older Aml Patients William
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationSystemic Treatment of Acute Myeloid Leukemia (AML)
Guideline 12-9 REQUIRES UPDATING A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Treatment of Acute Myeloid Leukemia (AML) Members of the Acute Leukemia
More informationKey Words. Acute myeloid leukemia Elderly Chemotherapy Gemtuzumab ozogamicin Bone marrow transplantation
The Oncologist Geriatric Oncology Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly JACOB LAUBACH, ARATI V. RAO Division of Medical Oncology, Duke University Medical
More informationEmerging Treatment Options for Myelodysplastic Syndromes
Emerging Treatment Options for Myelodysplastic Syndromes James K. Mangan, MD, PhD Assistant Professor of Clinical Medicine Abramson Cancer Center, University of Pennsylvania Please note that some of the
More informationHighlights in acute myeloid leukemia (AML): what is going to change?
29 Highlights in acute myeloid leukemia (AML): what is going to change? C. Graux, MD, PhD SUMMARY The decision making process in AML integrates clinical features, an increasing amount of genetic information
More informationNovel Induction and Targeted Strategies in Acute Myeloid Leukemia
Novel Induction and Targeted Strategies in Acute Myeloid Leukemia Eytan M. Stein, MD Leukemia Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Current Paradigms
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationThe Past, Present, and Future of Acute Myeloid Leukemia
The Past, Present, and Future of Acute Myeloid Leukemia Carter T. Davis, MD Hematology-Oncology Fellow Duke University Health System September 10, 2016 Overview Overview of Acute Myeloid Leukemia Review
More informationMRD detection in AML. Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome
MRD detection in AML Adriano Venditti Hematology Fondazione Policlinico Tor Vergata Rome Determinants of Treatment Response Leukemia Tumor burden Growth potential Drug resistance Karyotype Genetics Host
More informationAmerican Society of Hematology Annual Meeting, San Diego, CA USA, 2 Dec 2018
Uproleselan (GMI-1271), an E-selectin antagonist, improves efficacy and safety of chemotherapy in R/R and newly diagnosed older patients with AML: final, correlative, and subgroup analyses Daniel J. DeAngelo,
More informationProgress in the treatment of acute promyelocytic leukemia. Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University
Progress in the treatment of acute promyelocytic leukemia Lionel Adès, MD PhD Hopital Saint Louis, Paris Diderot University 대한혈액학회 Korean Society of Hematology COI disclosure Name of author : Lionel Adès
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationTherapeutic landscape in AML
Therapeutic landscape in AML Andrew Wei 1955: From the sea to Ara-C Cryptotethya crypta Werner Bergman Robert Feeney Bergmann W. & Burke D. C. 1955. Marine products. The nucleosides of sponges. 3: Spongothymidine
More informationUpdate on Optimal Management of Acute Myeloid Leukemia
Update on Optimal Management of Acute Myeloid Leukemia Fuad El Rassi, Emory University Martha Arellano, Emory University Journal Title: Clinical Medicine Insights: Oncology Volume: Volume 7 Publisher:
More informationBest of ASH: Acute leukemia. Frédéric Baron
Best of ASH: Acute leukemia Frédéric Baron I Acute Myeloid Leukemia Flt3 inhibitors (ratify, sorafenib after HCT) 5 other important abstracts (in brief) Mutated genes in AML FLT3: The Cancer Genome Atlas
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationAre we always prolonging survival?
New therapies for myelodysplastic syndromes beyond hypomethylating agents and IMIDs Valeria Santini UF Ematologia, Università di Firenze Lisbon, May 4 th, 2012 Are we always prolonging survival? 1 Survival
More informationTHE LEUKEMIAS. Etiology:
The Leukemias THE LEUKEMIAS Definition 1: malignant transformation of the pluripotent stem cell, successive expansion of the malignant clone from the bone marrow to the tissues Definition 2: Heterogenous
More informationManagement of low and high risk MDS
Management of low and high risk MDS D.Selleslag AZ Sint-Jan Brugge, Belgium Brussels, 4th October 2014 Low / int 1 risk MDS Improve QOL Improve cytopenia Int 2 / high risk MDS Delay progression To AML
More informationAdvances in CLL 2016
Advances in CLL 2016 The Geoffrey P. Herzig Memorial Symposium, Louisville, KY Kanti R. Rai, MD Northwell-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Disclosures Member
More informationBendamustine for Hodgkin lymphoma. Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service
Bendamustine for Hodgkin lymphoma Alison Moskowitz, MD Assistant Attending Memorial Sloan Kettering, Lymphoma Service Bendamustine in Hodgkin lymphoma Bifunctional molecule Nitrogen mustard component (meclorethamine)
More informationSingle Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia
Single Technology Appraisal (STA) Midostaurin for untreated acute myeloid leukaemia Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Please note: Comments
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationMinimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials
Minimal Residual Disease as a Surrogate Endpoint in Acute Myeloid Leukemia Clinical Trials Fda.gov Adriano Venditti Hematology, University Tor Vergata, Rome, Italy Minimal Residual Disease 10 12 Relapse
More information